Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

The art of building a biologic drug

The first biosimilar from Xbrane Biopharma was launched earlier this year, and several more are under development at the company’s facility in Solna, Sweden. “W...

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...

TCO easy comparison of electric and pneumatic solutions

Find the right technology for your application and compare CO₂ emission and TCO The shown results are not based on a sizing calculation, parameters like service...

He saved lives with his theories – was ostracised and ended up in a mental hospital

Hungarian doctor Ignaz Semmelweis (1818-1865) undoubtedly possessed plenty of persistence, diligence and sound reasoning skills – but he was hardly blessed with...

Standardisation in automation

B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...

Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”

It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless differ...

Sedana får ny CFO

Susanne Andersson efterträder Maria Engström.

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”

When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, abou...

Astrazeneca får särläkemedelsstatus

COMP rekommenderar att läkemedelskandidaten acalabrutinib får särläkemedelsstatus mot tre olika blodcancerformer i EU.

EMA vill se mer särläkemedel

Antalet godkända särläkemedel i EU har fördubblats de senaste två åren. Nu gör EMA riktade satsningar för att trenden ska fortsätta.

Tre experter till PCG

Antonio Mastroianni, Heidi Pavliska och Roger Price tar plats på kontraktsforskningsbolaget.

Läkemedelsbolag ratar Trump

Flera tunga ledare har lämnat Donald Trumps industriråd i protest mot presidentens svaga agerande i samband med kravallerna i amerikanska Charlottesville. Tydli...

Pilots want to live too

Särläkemedelsstatus för Respiratorius

- Särläkemedel är populära bland många läkemedelsföretag, alltså våra potentiella partners, bland annat eftersom de får marknadsexklusivitet men även då utveckl...

Tikomed får särläkemedelsstatus

EU:s kommitté för särläkemedel har beviljat särläkemedelsstatus för preparatet Ibsolvmir. Substansen utvecklas för att förhindra avstötning vid transplantation ...

Lundbeck divests companies

The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.

Changing e-solutions for clinical trials

Social media and personalized medicine are two factors that will have a great impact on the design and IT-solutions for clinical trials. Unithink is an upcoming...

Big Pharma blir sig inte likt

I veckan släppte Price Waterhouse Coopers, PwC, sin rapport om läget för den globala läkemedelsindustrin fram till 2020. Stora strukturella förändringar krävs i...

Ideon - Sweden's oldest science park

Old is not synonymous with boring. Swedens oldest science park Ideon still manages to attract young companies with big ideas. The recipe for success? To continu...

Early stage research and low turnaround dominates

Nordic science parks are full of advanced research performed by small companies but little research is done in later stages. Only a couple of the best performer...

Ny era för läkemedelsstudier

- Det här kräver en total omställning, säger Jan Trøst Jørgensen som forskar inom personalized medicne.